Bristol-Myers Squibb Company (NYSE:BMY) – Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE

[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending that Eliquis . . . → Read More: Bristol-Myers Squibb Company (NYSE:BMY) – Eliquis® (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE Similar Articles: Stock Update (NYSE:BMY): Bristol-Myers Squibb Announces Dividend Company Update (NYSE:BMY): Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List Company Update – Bristol-Myers Squibb Company (NYSE:BMY) – Xigduo™ (dapagliflozin and metformin hydrochloride) receives positive CHMP opinion in the European Union for the treatment of type 2 diabetes
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.